ArticlePloS one2026
Global lung cancer burden, trends, and projections from 2010 to 2050: A population-level severity framework integrating DALYs-per-case and mortality-to-incidence ratio.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer remains the leading cause of cancer mortality worldwide. While incidence and mortality describe population burden, they do not fully capture disease severity at the level of the individual patient. This study quantified the contemporary global burden, temporal trends, and future trajectory of tracheal, bronchus, and lung (TBL) cancer, and applied a multidimensional severity framework integrating fatal and non-fatal outcomes.
methodsA global ecological analysis was conducted across 185 countries and territories using harmonized data from GLOBOCAN 2022, the Global Burden of Disease (GBD) 2023 study, and the UN World Population Prospects 2024. Contemporary burden was assessed using incident cases, deaths, age-standardized incidence and mortality rates (ASIR/ASMR), disability-adjusted life years (DALYs), mortality-to-incidence ratio (MIR), and DALYs per incident case. Temporal trends in ASIR and ASMR (2010-2023) were estimated using log-linear regression to derive average annual percent change (AAPC). Projections to 2050 were generated under two scenarios: (1) constant 2022 rates reflecting demographic change only, and (2) trend-based projections extrapolating country-specific AAPCs. Disease severity was evaluated using a two-dimensional framework combining MIR and DALYs-per-case, which captures average lifetime health loss per diagnosed individual independent of population size or age structure.
resultsIn 2022, an estimated 2.48 million new TBL cancer cases and 1.82 million deaths occurred globally, corresponding to ASIR and ASMR of 23.6 and 16.8 per 100,000, respectively. Global DALYs reached 46.7 million, yielding 18.8 DALYs per case, with substantially higher burden in males and in higher-SDI regions. From 2010-2023, age-standardized rates increased in most low- and middle-income countries and declined predominantly in high-income settings. By 2050, demographic change alone is projected to drive large increases in burden in many low-resource countries, with further amplification under trend-based scenarios. DALYs-per-case showed a moderate positive correlation with MIR (Spearman's r_s = 0.46), revealing marked heterogeneity in severity profiles across countries.
conclusionsGlobal lung cancer burden is projected to rise substantially in many regions despite declining rates in high-income settings. Integrating DALYs-per-case with MIR provides a complementary severity lens that highlights inequities not captured by incidence and mortality alone and supports more targeted prevention, treatment, and survivorship strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.